PI
NRIX icon

Putnam Investments’s Nurix Therapeutics NRIX Stock Holding History

Putnam Investments’s Portfolio NRIX Stock Details NRIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		$637K Buy
+61,717
New +$423K ﹤0.01% 904

Other funds holding NRIX

Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return

Putnam Investments's NRIX Position: Q4 2023 in Review

Putnam Investments opened a new position in Nurix Therapeutics (NRIX) in Q4 2023: 61,717 shares worth $637K. The stake represents ﹤0.01% of the portfolio and ranks #904 among its holdings.

130 funds tracked by Wall St. Rank hold NRIX as of Q4 2023.

  • Putnam Investments held 61,717 shares of Nurix Therapeutics worth $637K as of Q4 2023.
  • Nurix Therapeutics was a new Putnam Investments position in Q4 2023.
  • Nurix Therapeutics made up ﹤0.01% of Putnam Investments's portfolio in Q4 2023, its #904 holding.
  • 130 funds tracked by Wall St. Rank held Nurix Therapeutics as of Q4 2023.

Based on Putnam Investments's 13F filing for Q4 2023, filed 14 Feb 2024.